{"id":"W2806145489","doi":"10.1200/jco.2018.36.18_suppl.lba9000","title":"IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Carboplatin; Atezolizumab; Paclitaxel; Internal medicine; Docetaxel; Oncology; Population; Chemotherapy; Cisplatin; Cancer; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01359561,0.0005284454,0.009121289,0.001173556,0.00009209454,0.00001638742,0.0004024433,0.0007392917,0.0004723084],"category_scores_gemma":[0.007208494,0.0003495613,0.001902603,0.001649527,0.001497969,0.0002364259,0.0001207082,0.001204257,0.00000152192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004420983,"about_ca_system_score_gemma":0.002631617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001537257,"about_ca_topic_score_gemma":0.001787672,"domain_scores_codex":[0.9856769,0.002798105,0.009245791,0.0006395704,0.001067443,0.0005721409],"domain_scores_gemma":[0.9809067,0.009990628,0.006697854,0.000735539,0.001200642,0.0004686813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8461843,0.0100485,0.01565015,0.00007304301,0.009213973,0.0003874851,0.004483425,0.00001790184,0.004506634,0.00001918345,0.0001611312,0.1092543],"study_design_scores_gemma":[0.765241,0.1067688,0.1152201,0.0003150722,0.004749873,0.000177757,0.004132096,0.0005099479,0.000395301,0.0001326086,0.001984261,0.0003730887],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896818,0.004306344,0.000088044,0.001215178,0.0007982283,0.002189916,0.00005125007,0.0000170846,0.00165219],"genre_scores_gemma":[0.9918438,0.005029446,0.001150023,0.001208289,0.0004145148,0.00003872621,0.00001591013,0.00005071915,0.0002485267],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1088812,"threshold_uncertainty_score":0.9998956,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05384313562783741,"score_gpt":0.4520079957856368,"score_spread":0.3981648601577993,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}